10-Q · May 13, 2026
Milestone Scientific reported a revenue decrease of approximately 3% from the prior year, coming in at $2.16 million. Loss from operations improved significantly, down to $828,000 from nearly $2 million a year ago,…
Earnings analysis · 10-Q
MLSS earnings analysis
Filed August 13, 2026 · Our reading of the company's report
The latest report
The extracted filing indicates some operational improvement, including positive operating cash flow for the six months ended June 30, 2026 and China revenue of $498,000 versus $0 in the prior period. However, total…
Read full summary
The extracted filing indicates some operational improvement, including positive operating cash flow for the six months ended June 30, 2026 and China revenue of $498,000 versus $0 in the prior period. However, total quarterly revenue, margins, EPS, cash, debt, inventory, receivables, and free cash flow were not included in the provided filing extract, preventing a complete income-statement and balance-sheet trend assessment. The most material concerns are going-concern uncertainty, stockholders' equity of approximately $3.5 million below NYSE American thresholds, potential delisting by April 8, 2027, and substantial dilution from the 7,962,963-unit private placement and related warrants.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
China Revenue Recovered
Revenue from China increased to $498,000 during the three months ended June 30, 2026, compared with $0 in the prior period, indicating renewed activity in that market.
-
Six-Month Operating Cash Flow Positive
Management reported positive operating cash flow for the six months ended June 30, 2026, although the filing did not provide the amount in the extracted text.
-
Private Placement Added Capital
The company completed an April 2026 private placement of 7,962,963 units at $0.27 per unit, increasing stockholders' equity and supporting near-term liquidity.
-
Controls Remained Effective
Disclosure controls and procedures were concluded to be effective at a reasonable assurance level as of June 30, 2026, and no material internal-control changes were reported for the quarter.
What to watch
-
NYSE American Delisting Risk
As of June 30, 2026, reported stockholders' equity was approximately $3.5 million, below NYSE American continued-listing thresholds of $4 million and $6 million. The company must regain compliance by April 8, 2027 or face potential delisting procedures.
-
Significant Dilution Overhang
The April 2026 financing increased outstanding shares by approximately 10%, while exercise of the associated warrants could create an additional approximately 10% dilution and generate up to approximately $2.69 million in gross proceeds. Approximately $449,000 of convertible-note principal also remained outstanding at a conversion price not less than $0.50 per share.
-
China Trade and Supply Risk
The company sources important product components from China and reported $498,000 of China revenue during the quarter. New or proposed tariffs and U.S.-China trade measures could simultaneously increase sourcing costs and disrupt access to Chinese suppliers or customers.
-
Going Concern Remains
The company continues to incur operating losses and stated that limited cash resources raise substantial doubt about its ability to continue as a going concern. Although operating performance improved during the six months ended June 30, 2026, management cautioned that positive cash flows may not be sustained.
-
Medical Commercialization Uncertainty
Medical-product adoption remains uncertain despite FDA 510(k) clearance, CE mark approval, and a Category III CPT code. The company maintained a material allowance against slow-moving medical finished-goods inventory, and reimbursement uncertainty may prevent recovery of medical inventory and commercialization investments.
Management's outlook
No quantitative revenue or EPS guidance was provided in the extracted 10-Q. Outlook was deferred to the earnings press release or call.
Earlier filings 4
10-K · May 5, 2026
Milestone Scientific reported a decline in revenue and continued net losses over 2025, with total annual revenue stagnating at $2 million per quarter throughout the year. The company is focusing on scaling operations…
10-K · March 31, 2026
Milestone Scientific positions itself as a platform company built around its DPS (Dynamic Pressure Sensing) technology, with established dental adoption (STA/Wand used in more than 95 million injections) and an…
10-Q · November 13, 2025
Milestone Scientific reported product sales of $2,360,117 for Q3 2025 and a net loss of $1,153,959 (EPS $(0.01)), with operating loss improving to $(1,134,471). Management continues to disclose substantial doubt about…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.